Login
Navigate Fool.com
Will LXRX beat
the market?
Community Rating: 2 Stars: Unattractive

1.63 0.08 (5.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.56
Previous Close $1.55
Daily Range $1.50 - $1.64
52-Week Range $1.39 - $3.18
Market Cap $837.5M
P/E Ratio -8.15
Dividend (Yield) $0.00 (0.0%)
Volume 1,410,431
Average Daily Volume 1,588,039
Current FY EPS -$0.16

How do you think LXRX
will perform against the market?

Top LXRX Bull/Bear Pitches

 

sandybdr (< 20)
Submitted August 16, 2011

Biopharma company that works on mouse genetics , localizes potential drug targets , and then attempts to make drugs specific for those targets. Completely speculative play. If LX4211 succeeds (phase I … More

0 Replies Reply Report this Post
 

Brosan (1.25)
Submitted January 28, 2011

With more less than 80c per share available in cash, LXRX will have a very hard time to keep their heads above water. The me-too compound, LX4211, seems to be stuck in the ground due to the lack of in … More

1 Replies Reply Report this Post

News & Commentary

This Week in Biotech: Diabetes Patients Chalk Up 2 Impressive Victories

Legal settlements and victories, an FDA approval, and two positive clinical results take center stage in this holiday-shortened week in the biotech sector.

Could This Small-Cap Biotech's Experimental Diabetes Drug Be a Game Changer?

This Texas-based biotech reported positive proof-of-concept results earlier this week and could be set to upend a number of big pharmaceutical companies if its experimental drug continues to deliver.

Mid-Morning Market Update: Markets Open Higher; Citigroup Results Beat Estimates

Today’s Top Biotech Stories: Lexicon, Alimera, and Akebia

Lexicon, Alimera, and Akebia are the top stories to watch in the biotech sector this Monday morning.

Sector Update: Healthcares Flat to Lower Pre-Market; Lexicon Soars 20% on Study of Diabetes Treatmen

Sector Update: Healthcares Flat to Lower Pre-Market; Lexicon Soars 20% on Study of Diabetes Treatment

Lexicon Pharmaceuticals up 25% on drug trial

3 Stocks Near 52-Week Lows Worth Buying

Do Procera, Barclays, and Lexicon Pharmaceuticals deserve a second chance? You be the judge!

3 Biotech Companies That Could Be the Next Intercept or InterMune

With Intercept and InterMune stocks jumping 525% and 171%, respectively, biotech-savvy investors are eagerly looking for the next big thing. It just might be one of these three companies.

Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart

Lexicon Pharmaceuticals will focus its efforts on late-stage drug development, which will lead to the loss of 115 jobs.

Neurocrine Biosciences Inc. Nearly Doubles (but Not Really)

Neurocrine Biosciences isn't up nearly as much as it appears.

See More LXRX News...

Sector

Healthcare

Industry

Drugs

Lexicon Pharmaceuticals, Inc. (LXRX) Description

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Website: http://www.lexicon-genetics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks